205 related articles for article (PubMed ID: 37160705)
1. Molecular insights in repurposing selective COX-2 inhibitor celecoxib against matrix metalloproteinases in potentiating delayed wound healing: a molecular docking and MMPB/SA based analysis of molecular dynamic simulations.
Mude L; Jupudi S; Swaroop AK; Tallapaneni V; Karri VVSR
J Biomol Struct Dyn; 2024 Mar; 42(5):2437-2448. PubMed ID: 37160705
[TBL] [Abstract][Full Text] [Related]
2. Molecular Dynamics Simulations of Matrix Metalloproteinase 13 and the Analysis of the Specificity Loop and the S1'-Site.
Choi JY; Chung E
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445757
[TBL] [Abstract][Full Text] [Related]
3. Anti-aging activity of Syn-Ake peptide by
Gok B; Budama-Kilinc Y; Kecel-Gunduz S
J Biomol Struct Dyn; 2024 Jul; 42(10):5015-5029. PubMed ID: 37349941
[TBL] [Abstract][Full Text] [Related]
4. Assessing structural insights into in-house arylsulfonyl L-(+) glutamine MMP-2 inhibitors as promising anticancer agents through structure-based computational modelling approaches.
Baidya SK; Banerjee S; Ghosh B; Jha T; Adhikari N
SAR QSAR Environ Res; 2023; 34(10):805-830. PubMed ID: 37850742
[TBL] [Abstract][Full Text] [Related]
5. Molecular interactions of tannic acid and matrix metalloproteinases 2 and 9.
Chiang YT; Xiao YB; Hsu SH; Chang SW; Chou CC
Comput Struct Biotechnol J; 2023; 21():2792-2800. PubMed ID: 37181658
[TBL] [Abstract][Full Text] [Related]
6. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
Rashid ZA; Bardaweel SK
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
[TBL] [Abstract][Full Text] [Related]
7. Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface display.
Hosseini A; Kumar S; Hedin K; Raeeszadeh-Sarmazdeh M
Protein Sci; 2023 Dec; 32(12):e4795. PubMed ID: 37807423
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
9. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
[TBL] [Abstract][Full Text] [Related]
10. A fragment-based exploration of diverse MMP-9 inhibitors through classification-dependent structural assessment.
Baidya SK; Banerjee S; Ghosh B; Jha T; Adhikari N
J Mol Graph Model; 2024 Jan; 126():108671. PubMed ID: 37976979
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
12. In silico trials to design potent inhibitors against matrilysin (MMP-7).
Katari SK; Pasala C; Nalamolu RM; Bitla AR; Umamaheswari A
J Biomol Struct Dyn; 2022; 40(22):11851-11862. PubMed ID: 34405760
[TBL] [Abstract][Full Text] [Related]
13. Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors: Synthesis, Anti-inflammatory Activity and Molecular Docking Studies.
Madhava G; Ramana KV; Sudhana SM; Rao DS; Kumar KH; Lokanatha V; Rani AU; Raju CN
Med Chem; 2017; 13(5):484-497. PubMed ID: 28228088
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation.
Kalva S; Agrawal N; Skelton AA; Saleena LM
Mol Biosyst; 2016 Jul; 12(8):2519-31. PubMed ID: 27250644
[TBL] [Abstract][Full Text] [Related]
15. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant, Wound Healing Potential and In Silico Assessment of Naringin, Eicosane and Octacosane.
Balachandran A; Choi SB; Beata MM; Małgorzata J; Froemming GRA; Lavilla CA; Billacura MP; Siyumbwa SN; Okechukwu PN
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770709
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a sesquiterpene as possible drug lead against gelatinases via molecular dynamics simulations.
Jamal S; Ahmed A; Moin ST
J Biomol Struct Dyn; 2021 Mar; 39(5):1645-1660. PubMed ID: 32174257
[TBL] [Abstract][Full Text] [Related]
18. Structural insights into the binding mode of flavonols with the active site of matrix metalloproteinase-9 through molecular docking and molecular dynamic simulations studies.
Pradiba D; Aarthy M; Shunmugapriya V; Singh SK; Vasanthi M
J Biomol Struct Dyn; 2018 Nov; 36(14):3718-3739. PubMed ID: 29068268
[TBL] [Abstract][Full Text] [Related]
19. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
[TBL] [Abstract][Full Text] [Related]
20. Computational and In Vitro Investigation of (-)-Epicatechin and Proanthocyanidin B2 as Inhibitors of Human Matrix Metalloproteinase 1.
Lee KE; Bharadwaj S; Yadava U; Kang SG
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32998374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
